Akèy › Maladi fwa steatotik › Texas › Dallas
Etid klinik pou Maladi fwa steatotik nan Dallas, TX
9 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
- Methodist Dallas Medical Center, Dallas
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
- Akero Clinical Study Site, Dallas
- Akero Clinical Study Site, Dallas
- Akero Clinical Study Site, Dallas
- ak 1 plis
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Ap rekriteFaz 2
- GSK Investigational Site, Dallas
- GSK Investigational Site, Dallas
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Ap rekriteFaz 2
- GSK Investigational Site, Dallas
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
Ap rekriteEtid obsèvasyon
- Methodist Dallas Medical Center, Dallas
Etid Maladi fwa steatotik nan lòt vil
- San Antonio, TX17 etid
- New York City, NY16 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Richmond, VA12 etid
- Tucson, AZ10 etid
- Chandler, AZ10 etid
- Hialeah, FL9 etid
- Orlando, FL9 etid
- St. Louis, MO9 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè vejik27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.